We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we ...
Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Teva Pharmaceutical (NYSE: TEVA) and Sanofi (NASDAQ: SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...
Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...
Newsable Asianet News on MSN4d
Teva Stock Surges To 6-Year High On Inflammatory Bowel Disease Drug Trial Data: Retail Chatter EruptsShares of Teva Pharmaceutical Industries surged more than 23% on Tuesday afternoon, reaching levels not seen since December ...
Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of ...
Sanofi and Teva report positive Phase IIb results for duvakitug in ulcerative colitis and Crohn's disease, meeting primary ...
The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback